|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Etiology and long-term outcome of extrahepatic portal vein obstruction in children显示文摘AIM:To study the management and outcome of children with extrahepatic portal vein obstruction(EHPVO) in a whole country population.METHODS:A nationwide multicenter retrospective case series of children with EHPVO was conducted.Data on demographics,radiographic studies,laboratory workup,endoscopic and surgical procedures,growth and development,were extracted from the patients' charts.Characteristics of clinical presentation,etiology of EHPVO,management and outcome were analyzed.RESULTS:Thirty patients,13 males and 17 females,19(63.3%) Israeli and 11(36.7%) Palestinians,were included in the analysis.Age at presentation was 4.8± 4.6 years,and mean follow-up was 4.9±4.3 years.Associated anomalies were found in 4 patients.The incidence of EHPVO in Israeli children aged 0-14 years was 0.72/million.Risk factors for EHPVO were detected in 13(43.3%)patients,including 9 patients(30%) with perinatal risk factors,and 4 patients(13.3%) with prothrombotic states:two had low levels of protein S and C,one had lupus anticoagulant,and one was homozygous for methyltetrahydrofolate reductase mutations.In 56.6% of patients,no predisposing factors were found.The most common presenting symptoms were an incidental finding of splenomegaly(43.3%),and upper gastrointestinal bleeding(40%).No differences were found between Israeli and Palestinian children with regard to age at presentation,etiology and clinical symptoms.Bleeding occurred in 18 patients(60%),at a median age of 3 years.Sclerotherapy or esophageal banding was performed in 20 patients.No sclerotherapy complications were reported.Portosystemic shunts were performed in 11 patients(36.6%),at a median age of 11(range 3-17)years:splenorenal in 9,mesocaval in 1,and a meso-Rex shunt in 1 patient.One patient underwent splenectomy due to severe pancytopenia.Patients were followed up for a median of 3(range 0.5-15)years.One patient died aged 3 years due to mucopolysaccharidase deficiency type Ⅲ.None of the patients died due to gastrointestinal bleeding.CONCLUSION:EHPVO is a rare disorder.The etiological factors are still mostly unknown,and the endoscopic and surgical treatment options ensure a good long-term prognosis. | Batia Weiss Eyal Shteyer Asaf Vivante Drora Berkowitz Shimon Reif Zvi Weizman Yoram Bujanover Rivka Shapiro | 2010 | World Journal of Gastroenterology2010，16，39： | 6 |
| 2 | NOD2/CARD15 mutation analysis and genotype-phenotype correlation in Jewish pediatric patients compared with adults with Crohn’s disease显示文摘 | Batia Weiss Raanan Shamir Yoram Bujanover Mati Waterman Corina Hartman Akiva Fradkin Drora Berkowitz Ilana Weintraub Ram Eliakim Amir Karban | 2004 | The Journal of Pediatrics2004，，2： | 2 |
| 3 | Biological control of Botrytis , Aspergillus and Rhizopus rots on table and wine grapes in Israel显示文摘 | Tirtza Zahavi Lea Cohen Batia Weiss Leonardo Schena Avinoam Daus Tania Kaplunov Johanan Zutkhi Ruth Ben-Arie Samir Droby | 2000 | Postharvest Biology and Technology2000，，2： | 1 |
| 4 | Idiopathic Pancreatitis Preceding the Diagnosis of Inflammatory Bowel Disease Is More Frequent in Pediatric Patients显示文摘 | Efrat Broide Iris Dotan Batia Weiss Michael Wilschanski Baruch Yerushalmi Aharon Klar Arie Levine | 2011 | Journal of Pediatric Gastroenterology and Nutrition2011，，6： | 1 |
| 5 | Improving taste and peel color of early-season Satsuma mandarins by combining high-temperature conditioning and degreening treatments显示文摘 | Zipora Tietel Batia Weiss Efraim Lewinsohn Elazar Fallik Ron Porat | 2010 | Postharvest Biology and Technology2010，，1： | 1 |
| 6 | Effects of polyethylene wax content and composition on taste, quality, and emission of off-flavor volatiles in 'Mor' mandarins 显示文摘 | RON PORAT BATIA WEISS LEA COHEN | 2005 | Postharvest Biology and Technology2005，38，3： | 1 |
| 7 | Idiopathic Pancreatitis Preceding the Diagnosis of Inflammatory Bowel Disease Is More Frequent in Pediatric Patients显示文摘 | Efrat Broide Iris Dotan Batia Weiss Michael Wilschanski Baruch Yerushalmi Aharon Klar Arie Levine | 2011 | Journal of Pediatric Gastroenterology and Nutrition2011，，6： | 1 |
| 8 | Polyposis syndromes in children and adolescents: a case series data analysis显示文摘 | Shlomi Cohen Anna Gorodnichenco Batia Weiss Aaron Lerner Amir Ben-Tov Ayala Yaron Shimon Reif | 2014 | European Journal of Gastroenterology & Hepatology2014，，9： | 1 |
| 9 | Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease显示文摘 | Shomron Ben–Horin Matti Waterman Uri Kopylov Miri Yavzori Orit Picard Ella Fudim Halim Awadie Batia Weiss Yehuda Chowers | 2013 | Clinical Gastroenterology and Hepatology2013，，： | 1 |
| 10 | Current therapy of pediatric Crohn's disease显示文摘Inflammatory bowel diseases(IBD), including Crohn's disease(CD) and ulcerative colitis, are chronic relapsing and remitting diseases of the bowel, with an unknown etiology and appear to involve interaction between genetic susceptibility, environmental factors and the immune system. Although our knowledge and understanding of the pathogenesis and causes of IBD have improved significantly, the incidence in the pediatric population is still rising. In the last decade more drugs and treatment option have become available including 5-aminosalicylate,antibiotics, corticosteroids, immunomodulators and biological agents. Before the use of anti-tumor necrosis factor(TNF)-α became available to patients with IBD, the risk for surgery within five years of diagnosis was very high, however, with anti-TNF-α treatment the risk of surgery has decreased significantly. In the pediatric population a remission in disease can be achieved by exclusive enteral nutrition. Exclusive enteral nutrition also has an important role in the improvement of nutritional status and maintained growth. In this review we summarize the current therapeutic treatments in CD. The progress in the treatment options and the development of new drugs has led to optimized tactics for achieving the primary clinical goals of therapy- induction and maintenance of remission while improving the patient's growth and overall well-being. | Avishay Lahad Batia Weiss | 2015 | World Journal of Gastrointestinal Pathophysiology2015，6，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员